Amgen announced that all Repatha (evolocumab) devices are now available at a 60% reduced list price. This includes the pre-filled syringe, the SureClick autoinjector, and the Pushtronex device, an ...

More common side effects of Repatha may include cold and flu-like symptoms, back pain, and injection site reactions. Mild Repatha side effects also include headache, fatigue, stomach cramping, and ...

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Amgen has announced a price reduction for Repatha (evolocumab), bringing the list price of the therapy to $5,850 per year, ...

Only inject Repatha (evolocumab) on its scheduled day. Do not inject a dose in advance. The timing of your Repatha dose on an injection day isn’t important, so you can adjust it as needed on that day.

Amgen announced that as part of the company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and ...

The FDA expanded Repatha's label to include adults at increased risk for MACE due to uncontrolled LDL-C, broadening access beyond those with diagnosed CVD. Repatha is now approved as a standalone ...

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our ...

In October, Amgen cut the price of a biweekly dose of its cholesterol drug Repatha by 60 percent. Now, the drugmaker has announced another 60 percent price slash, this time to the cost of a monthly ...

The FDA approved Amgen’s AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha’s approval comes a month ...

Repatha is the second in a new class of drugs called PCSK9 inhibitors to win FDA approval The drug is a second line of treatment for those who can't take or don't respond to widely used statins for ...

LONDON--Last Thursday's FDA approval for Amgen's PCSK9 competitor, Repatha, kicked off a head-to-head contest between that med and recently green-lighted Praluent from Sanofi and Regeneron. And with ...